Objective of the study: There is enough evidence for the carcinogenicity of HPV16 type in the head and neck cancers. This study aimed to address key information gaps of the prevalence of HPV infection in laryngeal squamous cell carcinoma in Azerbaijan population.Materials and methods: 50 LSCC pretreatment FFPE biopsy tumor materials, 10 cervical cancer FFPE samples and 38 fresh pretreatment LSCC tumor materials were analyzed using RT-PCR technology and Anyplex II HPV28 genotyping assay. The FFPE tumor material with HPV positive history from cervical cancer was as control in this study.Results: DNA extraction from FFPE and fresh samples was successful for all 98 tumor materials. The results of HPV genotyping of cervical cancer patients (n=10) with Anyplex II HPV28 assay detected 8 HPV16-positive cancers, 1 samples with HPV18-positive and 1 cancer material with HPV16+HPV18+HPV58. The results were predictable, because in these patients, HPV positivity was validated by Pap smear method. Based on this, we expect to get true information about HPV-related LSCC. Anyplex IIHPV28 genotyping assay was detected only one HPV positive sample of 61 LSCC: it was low-risk cancer-related HPV54 subtype in 47 age's patient with 20 years tobacco and alcohol consumption history. High-risk cancer related HPV16 and HPV18 subtypes have no detected in analysis patients. Conclusion:Thus, we suggested that PCR techniques and Anyplex II HPV28 genotyping assay were available to detect HPVs from fresh LSCC material. Our results support us to believe that Azerbaijan belongs to HPV lowincidence geographic region of laryngeal squamous cell carcinoma patients, but large-scale population-based studies are needed to confirm our findings.
Vasopressin and its receptors play a key role in maintaining homeostasis in physiological and pathophysiological conditions. As a result, the vasopressin system has become an important target for both diagnostic and therapeutic use in a number of diseases. Kopeptin, C-terminal part of vasopressin prohormone. Copeptin has come to be seen as an important marker for identifying high-risk patients and predicting outcomes for various diseases. This improves the clinical value of commonly used biomarkers and risk stratification tools. The area that could benefit most from the introduction of the copeptin measurement in practice is cardiovascular disease. Determination of the level of copeptin becomes a fast and reliable method of differential diagnosis, especially in acute coronary syndromes. A special role in the diagnosis of acute myocardial infarction (AMI) is given to the combination of copeptin and troponin. According to available sources, such a combination eliminates AMI with very high sensitivity and negative predictive value. Moreover, elevated levels of copeptin correlate with poorer prognosis, and a higher risk of side effects after AMI, especially in patients with heart failure.
Now there is a relevant development of the new biomarkers capable to serve as the instrument of early diagnostics of a disease for the purpose of selection of a pharmacotherapy and further monitoring of its efficiency. Galektin-3 is the atypical representative of the family of galektin. Its participation in fibrosis, remodeling of heart, the immunologic answer and inflammatory reactions are shown. Prognostic value is discussed and diagnostic opportunities of Galektin-3 at CHF are widely studied and take root into clinical practice. Now a great deal of research devoted to the studying of Galektin-3, possibilities of its use as a biomarker at diagnostics, forecasting of outcomes and the choice of therapeutic strategy at other cardiovascular diseases has been conducted.
Analysis of the prevalence of thyroid gland cancer (TGC) of the population of Azerbaijan over the period 2009-2015 showed a relatively unfavorable situation, as evidenced by the steady rise in the morbidity rate of this nosology. Over 7 years, there was noted the gain in coefficients of extensivity and intensity of the given pathology among the population of the Republic. Prevalence factor for TGC has increased till 2015 by almost 2 times (11.7 0/0000 vs. 5.20/0000). The peak of the incidence corresponds to the age group of 50-59 years (0.60/0000). Five-year survival for this nosology has tended to the decrease, and varied in the range of from 36.3% to 29.0%.
Objective. To evaluate the nature of changes in body fat composition in cirrhotic patients of various somatotypes.Materials and methods. The data of 46 cirrhotic patients and 20 volunteers were analyzed. Anthropometric examination was carried out according to methodological requirements with assessing the body composition of patients by means of bioimpedance analysis using ABC-01 Medass system (NTC Medass, Russia). Somatotypes were determined according to the Heath–Carter method. Ranks for the somatotype scale were assigned as endomorphy scores increased. Spearman rank correlation was used to identify the relationships between the variables. Differences between continuous variables were determined using the Mann–Whitney test. Statistical analysis was performed using Statistica 10 (StatSoft Inc., USA).Results. Child–Pugh scores for men and women were 9 (7.3–11.8) and 7 (6–9), respectively. Body fat percentage (BFP) of cirrhotic patients accounted for 27.7% (23.3–33) in men and 41.2% (33.6–46.3) in women. In healthy volunteers, the BFP was 21.9% (13.9–26.3) in men and 32.7% (29.3–41.6) in women. Assessment of the relationships between liver cirrhosis severity and body fat was characterized by a correlation coefficient of r = -0.47528 (p-value < 0.001). A significant negative correlation was determined between the liver cirrhosis severity according to Child–Pugh scores and somatotypes (r = -0.30536, p = 0.03905).Conclusion. The results of this study emphasize the correlation between somatotypes and changes in BFP in patients with liver cirrhosis of various degrees of severity. The sum of Child–Pugh scores and endomorphic indicators demonstrated the inverse relationship, which must be taken into account when developing mathematical models of the personalized prognosis of liver cirrhosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.